Dec
10
2019
On demand
Combining state-of-the-art production, purification and analytics to optimize AAV manufacturing for clinical and commercial gene therapies
Sponsor
Meeting the need for innovation in both upstream and downstream AAV viral vector bioprocess technology is a crucial step towards ensuring the continued emergence of the commercial gene therapy sector. A second and closely related one is evolving the analytics required to ensure consistent, robust and cost-effective manufacture. In this webinar, Thermo Fisher Scientific describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.
Attendees find out:
- How innovation in upstream technology will deliver process robustness and titer enhancement
- How to optimize and effectively scale up downstream bioprocess workflows in order to capitalize on increased upstream yields
- What is the latest thinking and innovation in developing the analytics needed to improve both the quality and efficiency of viral vector manufacture for gene therapy
- New regulatory paradigm for accelerated cell and gene therapy product development.
- Key points of future focus for further investment and collaboration
You might also like
Commercializing cell and gene therapies: Navigating complex commercial readiness hurdles for a successful product launch
Andrea Briggs
9 May 2023
in 39
Days
Environmental monitoring: optimizing microbial control in cell and gene therapy workflows
Nico Chow
27 April 2023
in 27
Days
Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells
Deepak Kumar
20 April 2023
in 20
Days
Analyzing full and empty AAV capsid ratio in less than 5 minutes
Åsa Hagner McWhirter
19 April 2023
in 19
Days
Development of anti-AAV assay for detection of pre-existing AAV immunity
Zhe Liu, John Chappell
18 April 2023
in 18
Days